The benefit seems durable, but one expert says patients should be aware there’s “some risk of stroke” during the procedure.

The overall evidence for the procedure is “insufficient” at present, but good enough to allow coverage, the agency says.

The data indicate it’s worth a shot to try TEER in many with secondary MR, but clinical judgement is critical.

Some believe that future studies are still needed to tease out whether there are high-risk subgroups who will benefit.

When encountering elderly ACS patients, clinical judgement is important given the risks of bleeding, says Arnold Seto.

There have been three deaths and no serious injuries tied to a problem affecting detection of the pumps, according to Abiomed ...

Gi-Byoung Nam, Duk-Woo Park, and C. Michael Gibson weigh edoxaban monotherapy vs dual antithrombotic therapy for patients with AF and stable coronary artery disease.

NEW YORK, NY—Real-world TAVI experience with the self-expanding Navitor valve (Abbott) shows a high rate of technical success with few events at 30 days, according to registry data. In almost 3,000 ...